Vicki A. Morrison

17.0k total citations · 3 hit papers
86 papers, 8.2k citations indexed

About

Vicki A. Morrison is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Vicki A. Morrison has authored 86 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pathology and Forensic Medicine, 36 papers in Oncology and 34 papers in Genetics. Recurrent topics in Vicki A. Morrison's work include Lymphoma Diagnosis and Treatment (40 papers), Chronic Lymphocytic Leukemia Research (33 papers) and CNS Lymphoma Diagnosis and Treatment (14 papers). Vicki A. Morrison is often cited by papers focused on Lymphoma Diagnosis and Treatment (40 papers), Chronic Lymphocytic Leukemia Research (33 papers) and CNS Lymphoma Diagnosis and Treatment (14 papers). Vicki A. Morrison collaborates with scholars based in United States, France and United Kingdom. Vicki A. Morrison's co-authors include Thomas F. Patterson, Dimitrios P. Kontoyiannis, Kieren A. Marr, John R. Wingard, David A. Stevens, William J. Steinbach, Raoul Herbrecht, David W. Denning, Brahm H. Segal and Thomas J. Walsh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Vicki A. Morrison

85 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

2008 1.9k citations Vicki A. Morrison et al. profile →
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

2016 1.8k citations Vicki A. Morrison et al. profile →
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

2006 997 citations Vicki A. Morrison, B. A. Peterson et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vicki A. Morrison United States	32	4.0k	3.6k	2.2k	1.9k	1.3k	86	8.2k
Georg Maschmeyer Germany	47	2.6k 0.6×	3.0k 0.8×	3.3k 1.5×	1.5k 0.8×	1.1k 0.9×	194	8.3k
Livio Pagano Italy	47	4.1k 1.0×	4.3k 1.2×	2.2k 1.0×	542 0.3×	926 0.7×	305	9.1k
Amelia Langston United States	41	2.4k 0.6×	2.7k 0.7×	2.1k 1.0×	757 0.4×	748 0.6×	177	7.5k
Nita L. Seibel United States	52	2.5k 0.6×	2.2k 0.6×	2.3k 1.1×	770 0.4×	581 0.4×	153	9.8k
Catherine Cordonnier France	65	4.8k 1.2×	7.5k 2.1×	3.9k 1.8×	632 0.3×	709 0.5×	246	13.1k
Mario A. Luna United States	71	1.9k 0.5×	2.9k 0.8×	6.5k 3.0×	1.8k 0.9×	379 0.3×	274	14.4k
Lionel Rostaing France	72	3.6k 0.9×	5.3k 1.5×	2.0k 0.9×	380 0.2×	526 0.4×	591	20.2k
Rodrigo Martino Spain	56	2.0k 0.5×	3.4k 0.9×	2.8k 1.3×	1.4k 0.7×	1.6k 1.3×	313	10.4k
Marc Boogaerts Belgium	29	1.8k 0.5×	1.8k 0.5×	1.1k 0.5×	455 0.2×	916 0.7×	115	5.4k
Denis Caillot France	46	2.7k 0.7×	2.4k 0.7×	2.8k 1.3×	418 0.2×	604 0.5×	198	8.4k

Countries citing papers authored by Vicki A. Morrison

Since Specialization

Citations

This map shows the geographic impact of Vicki A. Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vicki A. Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vicki A. Morrison more than expected).

Fields of papers citing papers by Vicki A. Morrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vicki A. Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vicki A. Morrison. The network helps show where Vicki A. Morrison may publish in the future.

Co-authorship network of co-authors of Vicki A. Morrison

This figure shows the co-authorship network connecting the top 25 collaborators of Vicki A. Morrison. A scholar is included among the top collaborators of Vicki A. Morrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vicki A. Morrison. Vicki A. Morrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Griggs, Jennifer J., Kari Bohlke, Edward P. Balaban, et al.. (2021). Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 39(18). 2037–2048. 75 indexed citations

Crawford, Jeffrey, Donald C. Moore, Vicki A. Morrison, & David C. Dale. (2021). Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage. Cancer Treatment and Research Communications. 29. 100466–100466. 5 indexed citations

Morrison, Vicki A., et al.. (2019). Treatment approaches for older and oldest patients with diffuse large B-cell lymphoma – Use of non-R-CHOP alternative therapies and impact of comorbidities on treatment choices and outcome: A Humedica database retrospective cohort analysis, 2007–2015. Journal of Geriatric Oncology. 11(1). 41–54. 7 indexed citations

Morrison, Vicki A., Yaping Shou, Jill A. Bell, et al.. (2019). Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study. Clinical Lymphoma Myeloma & Leukemia. 19(4). e172–e183. 16 indexed citations

Morrison, Vicki A., et al.. (2018). Treatment of mantle cell lymphoma in older adults. Journal of Geriatric Oncology. 9(4). 308–314. 4 indexed citations

Nipp, Ryan David, Lisa M. Lowenstein, Jan C. Buckner, et al.. (2016). Pragmatic study designs for older adults with cancer: Report from the U13 conference. Journal of Geriatric Oncology. 7(4). 234–241. 30 indexed citations

Morrison, Vicki A., et al.. (2015). How I treat chronic lymphocytic leukemia in older patients. Journal of Geriatric Oncology. 6(5). 333–340. 3 indexed citations

Morrison, Vicki A.. (2014). Infections in Patients with Leukemia and Lymphoma. Cancer treatment and research. 161. 319–349. 43 indexed citations

Morrison, Vicki A., Sin‐Ho Jung, Jeffrey L. Johnson, et al.. (2014). Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leukemia & lymphoma. 56(4). 958–964. 33 indexed citations

10.

Morrison, Vicki A., Paul A. Hamlin, Pierre Soubeyran, et al.. (2014). Diffuse large B-cell lymphoma in the elderly: Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) Expert Position Paper. Journal of Geriatric Oncology. 6(2). 141–152. 49 indexed citations

11.

Woyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, et al.. (2011). Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. Journal of Clinical Oncology. 29(10). 1349–1355. 102 indexed citations

12.

Blaes, Anne & Vicki A. Morrison. (2010). Post-transplant lymphoproliferative disorders following solid-organ transplantation. Expert Review of Hematology. 3(1). 35–44. 16 indexed citations

13.

Morrison, Vicki A.. (2010). Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Practice & Research Clinical Haematology. 23(1). 145–153. 124 indexed citations

14.

Hershman, Dawn L., et al.. (2009). Impact of primary prophylaxis on febrile neutropenia within community practices in the US. Journal of Medical Economics. 12(3). 203–210. 18 indexed citations

15.

Morrison, Vicki A.. (2009). Infectious Complications in Patients With Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum of Infection, and Approaches to Prophylaxis. Clinical Lymphoma & Myeloma. 9(5). 365–370. 90 indexed citations

16.

Morrison, Vicki A.. (2005). Caspofungin: an overview. Expert Review of Anti-infective Therapy. 3(5). 697–705. 8 indexed citations

17.

Lyman, Gary H., Vicki A. Morrison, David C. Dale, et al.. (2003). Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy. Leukemia & lymphoma. 44(12). 2069–2076. 181 indexed citations

18.

Morrison, Vicki A., Robert J. Haake, & Daniel J. Weisdorf. (1994). Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome. The American Journal of Medicine. 96(6). 497–503. 172 indexed citations

19.

Copenhaver, Cedith M., Vicki A. Morrison, Scott A. Gruber, et al.. (1992). B-cell lymphoproliferative disorders in solid-organ transplant patients: Detection of Epstein-Barr virus by in situ hybridization. Human Pathology. 23(2). 159–163. 30 indexed citations

20.

Morrison, Vicki A., B. A. Peterson, & Clara D. Bloomfield. (1990). Nosocomial septicemia in the cancer patient: The influence of central venous access devices, neutropenia, and type of malignancy. Medical and Pediatric Oncology. 18(3). 209–216. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact